These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3985888)

  • 21. Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility.
    Uijtdehaage SH; Stern RM; Koch KL
    Aviat Space Environ Med; 1993 Jan; 64(1):1-8. PubMed ID: 8424733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexamethasone mimicks the antimotion sickness effects of amphetamine and scopolamine.
    Kohl RL
    Acta Astronaut; 1986 Sep; 13(9):565-71. PubMed ID: 11538662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenytoin for motion sickness: clinical evaluation.
    Knox GW; Woodard D; Chelen W; Ferguson R; Johnson L
    Laryngoscope; 1994 Aug; 104(8 Pt 1):935-9. PubMed ID: 8052077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperventilation in a motion sickness desensitization program.
    Mert A; Bles W; Nooij SA
    Aviat Space Environ Med; 2007 May; 78(5):505-9. PubMed ID: 17539445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naloxone enhances motion sickness: endorphins implicated.
    Allen ME; McKay C; Eaves DM; Hamilton D
    Aviat Space Environ Med; 1986 Jul; 57(7):647-53. PubMed ID: 3741286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generalization of tolerance to motion environments.
    Dobie TG; May JG
    Aviat Space Environ Med; 1990 Aug; 61(8):707-11. PubMed ID: 2400373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Human susceptibility to motion sickness in combined vestibular and optokinetic stimulation with a reduced field of vision].
    Lapaev EV; Vorob'ev OA
    Izv Akad Nauk SSSR Biol; 1984; (4):496-500. PubMed ID: 6332835
    [No Abstract]   [Full Text] [Related]  

  • 30. Phenylthiocarbamide taste perception and susceptibility to motion sickness: linking higher susceptibility with higher phenylthiocarbamide taste acuity.
    Sharma K; Sharma P; Sharma A; Singh G
    J Laryngol Otol; 2008 Oct; 122(10):1064-73. PubMed ID: 18252010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal status and fluid electrolyte metabolism in motion sickness.
    Grigoriev AI; Nichiporuk IA; Yasnetsov VV; Shashkov VS
    Aviat Space Environ Med; 1988 Apr; 59(4):301-5. PubMed ID: 3370037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Motion sickness, vascular changes accompanying pseudo-coriolis-induced nausea.
    Johnson WH; Sunahara FA; Landolt JP
    Aviat Space Environ Med; 1993 May; 64(5):367-9. PubMed ID: 8503808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promethazine as a motion sickness treatment: impact on human performance and mood states.
    Cowings PS; Toscano WB; DeRoshia C; Miller NE
    Aviat Space Environ Med; 2000 Oct; 71(10):1013-22. PubMed ID: 11051308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of phenytoin in the prevention of motion sickness.
    Chelen W; Kabrisky M; Hatsell C; Morales R; Fix E; Scott M
    Aviat Space Environ Med; 1990 Nov; 61(11):1022-5. PubMed ID: 2256875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An appraisal of the value of vitamin B12 in the prevention of motion sickness.
    Kohl RL; Lacey CL; Homick JL
    Acta Astronaut; 1983 Apr; 10(4):219-24. PubMed ID: 11541554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of eleven steroid hormones following motion sickness.
    Stalla GK; Doerr HG; Bidlingmaier F; Sippel WG; von Restorff W
    Aviat Space Environ Med; 1985 Oct; 56(10):995-9. PubMed ID: 4062773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation between motion sickness susceptibility and vasovagal syncope susceptibility.
    Bosser G; Caillet G; Gauchard G; Marçon F; Perrin P
    Brain Res Bull; 2006 Jan; 68(4):217-26. PubMed ID: 16377427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aminalon as an agent for the prevention of motion sickness].
    Lapaev EV; Voinova II; Vorob'ev OA; Barmicheva NM
    Zh Ushn Nos Gorl Bolezn; 1978; (5):35-9. PubMed ID: 360685
    [No Abstract]   [Full Text] [Related]  

  • 39. Eye movements to yaw, pitch, and roll about vertical and horizontal axes: adaptation and motion sickness.
    Bos JE; Bles W; de Graaf B
    Aviat Space Environ Med; 2002 May; 73(5):436-44. PubMed ID: 12014602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diazepam as an anti-motion sickness drug.
    McClure JA; Lycett P; Baskerville JC
    J Otolaryngol; 1982 Aug; 11(4):253-9. PubMed ID: 7131636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.